Big Data: Moving From Artificial Trials To A Smarter Regulatory Process
This year the EU Big Data Task Force intends to deliver an EU-wide strategy on how big data can be used to support the development and evaluation of new medicines. The recent massive growth of data generated by various technologies, such as ‘omics, portable devices, the internet of things and even social media, gives this task force an urgency for pharma and regulators. Bruno Boulanger discusses the impact this will have on how the pharmaceutical industry gathers and delivers data in the future.
You may also be interested in...
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.